Letairis Prescribing Information
Download Full U.S. Prescribing Information, including BOXED WARNINGS
Adobe Acrobat Reader
Downloading files on this page requires the Adobe Acrobat Reader
|
|
Letairis® (ambrisentan)
| Study Number |
Study Title |
Study Summary |
| AMB-220 |
A Phase 2, Randomized, Double-Blind, Dose-Controlled, Dose-Ranging Multicenter Study of Ambrisentan (BSF 208075) Evaluating Exercise Capacity in Patients with Moderate to Severe Pulmonary Arterial Hypertension |
Download Study Summary |
| AMB-222 |
A Phase 2, Open-label, Multicenter Study Evaluating Ambrisentan in Subjects with Pulmonary Arterial Hypertension Who Have Previously Discontinued Endothelin Receptor Antagonist Therapy Due to Serum Aminotransferase Abnormalities |
Download Study Summary |
| AMB-320 |
ARIES-1: Ambrisentan in PAH — A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects with Pulmonary Arterial Hypertension |
Download Study Summary |
| AMB-321 |
ARIES-2: Ambrisentan in PAH — A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects with Pulmonary Arterial Hypertension |
Download Study Summary |
|
